drugset / Trial / NCT02512692
Gemcitabine-Cisplatin-90Y TARE for Unresectable Intrahepatic Cholangiocarcinoma
NaSingle-groupOpen-labelDevice feasibility
Summary
The purpose of this study is to determine the safety and maximum tolerated dose (MTD) of 90 Y TARE (Y90) in combination with gemcitabine and cisplatin in patients with unresectable intrahepatic cholangiocarcinoma (ICC).
Timeline
- Start
- 2015-07-21
- Primary completion
- 2021-03-19
- Completion
- 2021-03-19
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Cisplatin | Other / unclassified | 25 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 300 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 600 mg/m2 | — |
| Subject | Gemcitabine | Small molecule | 1000 mg/m2 | — |